Immunovant, Inc. IMVT
29.90 USD +0.86 (+2.96%)
At closeNov 5, 2026, 4:00 AM EST
29.47 -0.43 -1.44%
Pre-market · Nov 5, 4:00 AM ET
28.50 Day range 29.93
21.43 52-week range 45.42
- YTD
- +17.62%
- 1 year
- +23.60%
- Market cap
- 6.18B
- EPS (ttm)
- -2.82
- Shares out
- 206.55M
- Forward P/E
- -10.87
- YTD return
- +17.62%
- 1-year return
- +23.60%
- Volume
- 1.11M
- Avg volume
- 1.37M
- Open
- 29.82
- Previous close
- 29.04
- Day's range
- 28.50 – 29.93
- 52-week range
- 21.43 – 45.42
- Beta
- 0.94
- Analysts
- Buy
- Price target
- 48.88 (+63.5%)
- Earnings date
- Nov 9, 2026
2Y -0.44 (-1.45%)
Key statistics
- Enterprise value
- 5.20B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 8.39
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -238.70M
- Total cash
- 797.80M
- Total debt
- 0
- Return on equity
- -80.10%
- Short % of float
- 19.67%
- 50-day average
- 33.95
- 200-day average
- 32.07
Analyst view
Consensus: buy
Buy
Price target (mean) 48.88 +63.5% upside
Now 29.90
- Target (low)
- 30.00
- Target (mean)
- 48.88
- Target (high)
- 66.00
Ratings (0m) 17 13 buy · 4 hold · 0 sell
- Strong buy2
- Buy11
- Hold4
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.72212.
Financials — quick view
IMVT Revenue — quarterly 0
IMVT Net income — quarterly -153.22M
IMVT EPS — quarterly -0.75
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.73701 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.6289 | -0.75 | -0.12 | -19.26% |
| May 20, 2026 | Mar 31, 2026 | -0.59202 | -0.73 | -0.14 | -23.31% |
| Feb 6, 2026 | Dec 31, 2025 | -0.72 | -0.61 | +0.11 | +15.28% |
| Nov 10, 2025 | Sep 30, 2025 | -0.72 | -0.73 | -0.01 | -1.39% |
| Aug 11, 2025 | Jun 30, 2025 | -0.69 | -0.60 | +0.09 | +13.04% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 4, 2026 | JP Morgan | main | Overweight | Overweight |
| Jun 30, 2026 | Citigroup | main | Buy | Buy |
| May 26, 2026 | Guggenheim | main | Buy | Buy |
| May 22, 2026 | Truist Securities | main | Hold | Hold |
| May 21, 2026 | B of A Securities | main | Buy | Buy |
| May 21, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immunovant.com
News
Your note
Sign in to keep a note on IMVT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARNETT EVA RENEE | Chief Financial Officer | Sale | Apr 15, 2025 | 396,774 |
| GEFFNER MICHAEL | Officer | Sale | Oct 21, 2025 | 217,958 |
| GIRÃO TIAGO M | Chief Financial Officer | Sale | Jul 22, 2026 | 240,798 |
| GLORIA MELANIE | Chief Operating Officer | Sale | Aug 19, 2026 | 219,301 |
| LEVINE MARK S | Officer | Sale | Nov 19, 2024 | 319,228 |
| MACIAS WILLIAM L | Officer | Sale | Feb 18, 2025 | 357,353 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 7.84% | 16,186,469 | 483.98M | Jun 29, 2026 |
| Deep Track Capital, Lp | 4.52% | 9,341,151 | 279.30M | Jun 29, 2026 |
| Blackrock Inc. | 3.48% | 7,180,897 | 214.71M | Jun 29, 2026 |
| Farallon Capital Management LLC | 2.81% | 5,805,000 | 173.57M | Jun 29, 2026 |
| Baker Bros. Advisors, LP | 2.63% | 5,435,220 | 162.51M | Jun 29, 2026 |
| State Street Corporation | 2.24% | 4,617,005 | 138.05M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.47% | 5,092,337 | 152.26M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.26% | 2,600,086 | 77.74M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.09% | 2,251,148 | 67.31M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.02% | 2,107,163 | 63.00M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 0.91% | 1,881,798 | 56.27M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.68% | 1,408,872 | 42.13M | Aug 30, 2026 |